

**ICON ANNOUNCES OVER \$45 MILLION IN NET NEW BUSINESS AWARDS IN FOURTH QUARTER ENDED MAY 31, 2001**

Dublin, Ireland, Thursday, June 14, 2001 - ICON plc (NASDAQ: ICLR), - Speaking at the Goldman Sachs 22<sup>nd</sup> Annual Healthcare Conference in Dana Point, California today, Mr Peter Gray, the Chief Operating Officer of ICON announced that the company had been awarded over \$45 million of net new business in it's fourth quarter ended 31 May 2001. As a result, the company estimates that it has already booked 80% of forecast revenues for the financial year ended May 31, 2002.

“The continuing strength of our new order intake again emphasizes the underlying strength of pharmaceutical outsourcing”, said Mr Gray. “Driven by this, our revenue growth rate, excluding the impact of acquisitions, was approximately 24% for the year to May 31, 2001, and our operating margins continued to improve. In addition, ICON Laboratories, which we acquired a year ago continued its turnaround, with strong order intake in the quarter and growing profitability”.

The Company will announce its audited results for the quarter and year ended May 31, 2001, on July 24. A copy of Mr Grays presentation at the Goldman Sachs Conference can be found on the company web site [www.iconclinical.com](http://www.iconclinical.com) under Shareholder Services / Recent Presentations, A calendar of company planned announcements and presentations can also be found on the web site

ICON provides contract clinical research services to the global pharmaceutical industry. The company currently has 22 offices in 14 countries and almost 1,300 employees worldwide.

Information in this press release contains “forward looking statements”. These statements involve risks and uncertainties that could cause actual results to differ materially including, without limitation, actual operating performance, the ability to maintain large client contracts or enter into new contracts, the ability to manage the opening of new offices, and the ability to maintain client relationships. Additional factors that could cause actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission, including its Forms 20-F, 6-K, F-1 and S-8.

Source: ICON plc

Contact: Sean Leech, CFO 011-353-1-216 1100  
ICON plc

<http://www.iconclinical.com>